3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
5
Terminated
2
Recruiting
2
Unknown
1
Not yet recruiting
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
24
Carcinoma, Intraductal, Noninfiltrating
6
Breast Carcinoma In Situ
3
Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pinealoma
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Medulloblastoma
1
Infertility
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR Positive HER2 Negative Advanced Breast Cancer
1
Glioblastoma
1
ERα+ Breast Cancer
1
ER+ Breast Cancer
1
Anatomic Stage III Breast Cancer AJCC v8
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Tamoxifen
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT06979596
2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
250 enrolled